Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (131-140 of 199) with videos related to

Pageof 20
Sort By:
Breast Cancer Research and Treatment|May 31, 2012
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesAlbert C Chen, Ilenia Migliaccio, Mothaffar Rimawi, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
Ceramide-induced Endoplasmic Reticulum Stress as a Targetable Vulnerability in Endocrine Therapy-Resistant Breast CancerPurab Pal, Shweta Chitkara, Godwin K Sarpey, et al.
Molecular Cancer Therapeutics|March 30, 2018
Trastuzumab-Resistant HER2<sup>+</sup> Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, et al.
Cell Cycle (Georgetown, Tex.)|January 16, 2015
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cellsKaleigh Canfield, Jiaqi Li, Owen M Wilkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsMothaffar F Rimawi, Lisa S Wiechmann, Yen-Chao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2005
Neoadjuvant trastuzumab induces apoptosis in primary breast cancersSyed K Mohsin, Heidi L Weiss, M Carolina Gutierrez, et al.
Journal of Medicinal Chemistry|April 22, 2020
Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBPFangrui Wu, Yuanda Hua, Salma Kaochar, et al.
Breast Cancer Research and Treatment|April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trialChristian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
Molecular Cancer Research : MCR|June 3, 2026
Ceramide-induced endoplasmic reticulum stress reveals a targetable vulnerability in endocrine therapy-resistant breast cancerPurab Pal, Shweta Chitkara, Godwin K Sarpey, et al.
Pageof 20

Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
Breast Cancer Research and Treatment|May 31, 2012
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesAlbert C Chen, Ilenia Migliaccio, Mothaffar Rimawi, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
Ceramide-induced Endoplasmic Reticulum Stress as a Targetable Vulnerability in Endocrine Therapy-Resistant Breast CancerPurab Pal, Shweta Chitkara, Godwin K Sarpey, et al.
Molecular Cancer Therapeutics|March 30, 2018
Trastuzumab-Resistant HER2<sup>+</sup> Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, et al.
Cell Cycle (Georgetown, Tex.)|January 16, 2015
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cellsKaleigh Canfield, Jiaqi Li, Owen M Wilkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsMothaffar F Rimawi, Lisa S Wiechmann, Yen-Chao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2005
Neoadjuvant trastuzumab induces apoptosis in primary breast cancersSyed K Mohsin, Heidi L Weiss, M Carolina Gutierrez, et al.
Journal of Medicinal Chemistry|April 22, 2020
Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBPFangrui Wu, Yuanda Hua, Salma Kaochar, et al.
Breast Cancer Research and Treatment|April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trialChristian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
Molecular Cancer Research : MCR|June 3, 2026
Ceramide-induced endoplasmic reticulum stress reveals a targetable vulnerability in endocrine therapy-resistant breast cancerPurab Pal, Shweta Chitkara, Godwin K Sarpey, et al.
Pageof 20